Vaquero J, Lobe C, Tahraoui S, Claperon A, Mergey M, Merabtene F, Wendum D, Coulouarn C, Housset C, Desbois-Mouthon C, et al
However, decomposition was commonly neglected and only considered as a small effect [2733]
Abraham, P., Avenell, A., McGeoch, S
Another observational trial published in September 2024 found that semaglutide was associated with reduced opioid overdose risk in patients with comorbid type 2 diabetes and opioid use disorder, and a study published in July last year also found that semaglutide was associated with a lower risk of regular tobacco use in patients with type 2 diabetes who were tobacco smokers, with semaglutide-treated patients seeking fewer healthcare resources to treat their tobacco addiction
The success of oral semaglutide has validated this delivery route, spurring investments and expanding clinical pipelines for metabolic and gastrointestinal disorders